WASHINGTON, DC: U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla in the Oval Office of the White House as he announces a deal with Pfizer to lower drug prices on September 30, 2025. (Photo by Win McNamee/Getty Images) Getty Images

Pfizer and AstraZeneca’s recent drug-pricing deals with the Trump Administration mark a sharp shift in how Washington is approaching the pharmaceutical industry. Facing potential 100% tariffs, both companies agreed to lower prices and expand U.S. investment under a new framework that ties affordability to domestic production.

Pharmaceutical leaders should see this not as a one-time concession but as a structural reset. Each company must craft its own strategy, grounded in its portfolio, data and competitive position, to navigate a ma

See Full Page